期刊文献+

多发性骨髓瘤患者自体造血干细胞移植后感染的临床特征 被引量:4

The clinical features of infection in multiple myeloma undergoing autologous hematopoietic stem cell transplantation
原文传递
导出
摘要 目的 了解多发性骨髓瘤(MM)自体造血干细胞移植(ASCT)后感染的临床特点.方法 回顾性分析在中山大学附属第一医院住院诊治并接受ASCT治疗的37例MM患者,记录移植后6个月内的感染类型、时间、病原体以及疗效和转归.结果 在ASCT后6个月内有33例(89.2%)患者在观察期间出现59例次感染,其中30例患者在观察期间出现34例次(57.6%)细菌感染,12例患者在观察期间出现15例次(25.4%)真菌感染.既往曾合并真菌感染患者在移植后发生真菌感染比例高于没有合并真菌感染的患者(P=0.040).观察期间分别出现4例(6.8%)巨细胞病毒(CMV)、3例(5.1%)带状疱疹病毒感染及3例(5.1%)HBV再激活.移植后早期感染中细菌感染占62.8%,真菌感染28.6%,病毒感染8.6%,其中病毒感染均为CMV感染,移植后早期未见水痘带状疱疹病毒和HBV感染.移植后中期感染中细菌感染占50.0%、真菌感染20.8%、病毒感染29.3%,移植后早期与中期感染比例差异无统计学意义(P=0.106).38例次(64.4%)感染在应用首选抗感染治疗即得到控制.3例(8.1%)由于感染相关死亡.结论 MM患者ASCT后感染发生率高,各种病原体均易感,需要尽早合理抗感染治疗,降低感染相关病死率. Objective To explore the clinical features of infection in multiple myeloma (MM)undergoing autologous hematopoietic stem cell transplantation (ASCT). Methods Thirty-seven patients with MM undergoing ASCT were retrospectively analyzed for type and time of infection, pathogen, and outcome. Results Fifty-nine cases of infectious complications occurred in 33 patients (89. 2% ) after ASCT, with 34 cases (57.6%) of bacterial infections in 30 patients, 15 cases (25.4%) of fungal infections in 12 patients, 4 cases (6. 8% ) of cytomegalovirus (CMV) infection, 3 cases (5. 1% ) of herpes zoster virus infection and 3 cases (5. 1% ) of HBV reactivation. The proportion of bacterial infection, fungal infection and virus infection were 62. 8%, 28.6% and 8. 6% respectively in the early stage after ASCT, and 50. 0%, 20. 8% and 29. 3% respectively in the median stage. Response to first-line antibiotic therapy was seen in 38 cases (64. 4% ). Infection-related mortality was 8. 1% (3 cases). Conclusions The incidence of infection in MM patients undergoing ASCT is high and they are susceptible to all pathogens. It is important to choose the right antifungal agents as quickly as possible to reduce infection-related mortality.
出处 《中华内科杂志》 CAS CSCD 北大核心 2011年第1期44-47,共4页 Chinese Journal of Internal Medicine
关键词 多发性骨髓瘤 造血干细胞移植 感染 Multiple myeloma Hematopoietic stem cell transplantation Infection
  • 相关文献

参考文献3

二级参考文献16

  • 1黄晓军.血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(草案)[J].中华内科杂志,2005,44(7):554-556. 被引量:423
  • 2王景枝,刘代红,许兰平,陈欢,刘开彦,黄晓军.伊曲康唑在异基因造血干细胞移植患者真菌感染中的应用[J].中华内科杂志,2007,46(1):29-31. 被引量:7
  • 3Alexopoulou A, Theodorou M, Dourakis SP, et al. Hepatitis B Virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations[ J]. Journal of Viral Hepatitis,2006,13 ( 9 ) :591 - 596. 被引量:1
  • 4Jeong WJ, Jong YC, Si HB, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma [ J ]. Journal of Hepatology, 2004,41 : 427 - 435. 被引量:1
  • 5M Esteve, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis[ J]. Gut,2004,53 : 1363 - 1365. 被引量:1
  • 6Bernard YH, Ee TK, Hiok HC, et al. Outcomes of chronic hepatitis B infection in oriental patients with rheumatic diseases [ J ]. Ann Acad Med Singapore ,2007,36 : 100 - 105. 被引量:1
  • 7Kitano K, Kobayashi H, Hanamura M, et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region [ J ]. Eur J Haematology,2006,77 : 255 - 258. 被引量:1
  • 8Zubkin M, Balakirev E, Chervinko V, et al. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients[ J ]. Int J Artif Organs,2007,30 (4) : 308 - 314. 被引量:1
  • 9Yeo W,Chan PK,Ho WM,et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy[ J]. J Clin Oncol,2004,22 (5) :927 - 934. 被引量:1
  • 10Foont J, Schiff A, Eugene R. Avoid the tragedy of hepatitis B reactivation in immunosuppressed patients [ J ]. Nature Clinical Practice Gastroenterology & Hepatology,2007,4 ( 3 ) : 128 - 129. 被引量:1

共引文献342

同被引文献37

  • 1吕伟丽.多发性骨髓瘤肾损害的临床分析及护理[J].现代中西医结合杂志,2007,16(9):1256-1257. 被引量:3
  • 2Cavo M, Baccarani M. The changing landscape of myeloma thera- py. N Engl J Med, 2006, 354:1076-1078. 被引量:1
  • 3Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008,111:2516-2520. 被引量:1
  • 4Anderson KC, Alsina M, Bensinger W, et al. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw, 2009,7:908-942. 被引量:1
  • 5Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis, 2009, 49: 1211-1225. 被引量:1
  • 6Buser A, Stern M, Arber C, et al. Impaired B-cell reeonstitution in lymphonla patients undergoing allogeneie HSCT: an effect of pretreatment with rituximab?. Bone Marrow Transplant, 2008, 42:483-487. 被引量:1
  • 7Durie BG, Kyle RA, Belch A, et al. Myeloma management guide- lines: a consensus report from the Scientific Advisors of the Inter- national Myeloma Foundation. Hematol J, 2003, 4: 379-398. 被引量:1
  • 8Blad J, SamsonD, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and hemopoietic stem cell transplantation. Myeloma Subcommittee of the EMBT. European Group for Blood and Marrow Transplant. Br J Haematol, 1998,102 : 1115-1123. 被引量:1
  • 9Seder RA, Ahmed R. Similarities and differences in CD4 and CD8 effector and memory T cell generation. Nat Immunol, 2003, 4:835-842. 被引量:1
  • 10Reimer P, Kunzmann V, Wilhelm M, et al. Cellular and hurnoral immune reconstitution after autologous peripheral blood stem cell transplantation (PBSCT). Ann Hematol, 2003, 82 : 263 -270. 被引量:1

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部